These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32345708)

  • 21. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
    Dusetzina SB; Keating NL
    J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.
    Tseng CW; Brook RH; Keeler E; Steers WN; Mangione CM
    JAMA; 2004 Aug; 292(8):952-60. PubMed ID: 15328327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
    Daw JR; Morgan SG
    Health Policy; 2012 Jan; 104(1):19-26. PubMed ID: 21978939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The concentration and persistence of health care expenditures and prescription drug expenditures in Medicare beneficiaries with Alzheimer disease and related dementias.
    Lin PJ; Biddle AK; Ganguly R; Kaufer DI; Maciejewski ML
    Med Care; 2009 Nov; 47(11):1174-9. PubMed ID: 19786913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What Determines How Much Your Patient Pays for Their Medication in the United States?
    Novack GD
    Am J Ophthalmol; 2016 Jul; 167():48-51. PubMed ID: 27131775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Medicare Part D and insurance type on Medicare beneficiary access to prescription medication and use of prescription cost-saving measures.
    Urmie JM; Farris KB; Doucette WR; Goedken AM
    J Am Pharm Assoc (2003); 2011; 51(1):72-81. PubMed ID: 21247829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
    Padula WV; Ballreich J; Anderson GF
    Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examination of multiple medication use among TRICARE beneficiaries aged 65 years and older.
    Linton A; Garber M; Fagan NK; Peterson MR
    J Manag Care Pharm; 2007 Mar; 13(2):155-62. PubMed ID: 17330976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications?
    Allin S; Law MR; Laporte A
    Health Policy; 2013 May; 110(2-3):147-55. PubMed ID: 23522381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
    Trish E; Xu J; Joyce G
    Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.
    Tadrous M; Greaves S; Martins D; Mamdani MM; Juurlink DN; Gomes T
    CMAJ Open; 2018 Mar; 6(1):E132-E138. PubMed ID: 29581101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
    Hanley GE; Morgan S
    Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Professional Pharmacy Services and Patient Complexity: An Observational Study.
    Ignacy TA; Camacho X; Mamdani MM; Juurlink DN; Paterson JM; Gomes T
    J Pharm Pharm Sci; 2015; 18(5):863-70. PubMed ID: 26670372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of health plan design and management on retirees' prescription drug use and spending, 2001.
    Thomas CP; Wallack SS; Lee S; Ritter GA
    Health Aff (Millwood); 2002; Suppl Web Exclusives():W408-19. PubMed ID: 12703602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.